IL18 and hepatorenal syndrome: There are some studies showing that in patients with cirrhosis and progressive AKI, the combination of multiple urinary biomarkers, including uNGAL, KIM-1, Il-18, FABPs, and NAG, has a good ability to distinguish between ATN and non-ATN and to predict the progression of renal failure and the mortality rate; however, it does not have the capacity to diagnose an early hepatorenal syndrome [6,46,50].